PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 12, 2024Blood230 citationsOpen Access

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

HDHartmut DöhnerCDCourtney D. DiNardoFAFrederick Appelbaum

Key Points

  • Propose an updated European LeukemiaNet (ELN) genetic risk classification tailored specifically for adult patients with acute myeloid leukemia undergoing less-intensive therapy regimens.
  • Synthesized emerging clinical and genomic data from adult patients with acute myeloid leukemia receiving less-intensive treatment regimens.
  • Evaluated differences in prognostic utility compared to existing ELN frameworks derived from cohorts receiving intensive chemotherapy.
  • Formulated the 2024 ELN recommendations defining genetic risk categories specific to less-intensive therapy regimens.
  • Identified distinct prognostic implications of specific genetic abnormalities when managed with low-intensity approaches versus standard intensive chemotherapy.

Abstract

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Döhner et al. (2024) studied this question.

synapsesocial.com/papers/69d76fafaa68b335b4f31700https://doi.org/10.1182/blood.2024025409
Ask AI
Helpful
Bookmark
Share
View Full Paper